Gilead Sciences has agreed to pay $202 million to resolve allegations that it violated the Anti-Kickback Statute by using speaker programs to incentivize physicians to prescribe HIV medications.

Gilead will pay $202 million to resolve claims that it paid kickbacks to healthcare providers in the form of honoraria, meals ...

Dozens of trials on HIV ground to a halt in February after US President Donald Trump abruptly pulled crucial funding.

Gilead is committed to using its virology expertise to advance HIV treatment and prevention to help end the epidemic. Since 2010, the company has partnered with Emory University in Atlanta to launch A ...

Gilead held dinners to promote its HIV medications at expensive restaurants that federal authorities claim were “wholly inappropriate” venues, Stat reported. Gilead said it settled to avoid the cost ...

An ambitious plan to stop the global threat of AIDS has been derailed. But many are hopeful that progress can be salvaged.

Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

The company paid to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV ...

Over the years, a host of large drugmakers have inked settlements with the federal authorities to resolve allegations that ...

A New York doctor who treated HIV and AIDS patients sued Gilead for violating the False Claims Act with payments to doctors ...

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle claims it used speaker ...

ViiV leads the 2024/25 pharma company reputation rankings, with the PatientView report also finding ways in which the ...